vilanterol
Sign in to saveAlso known as GW642444X, GW-642444x, vilantérol, 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
Vilanterol is an ultra-long-acting β2-adrenoceptor agonist which was approved in May 2013 in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD). The combination is also approved for the treatment of asthma in Canada, Europe, Japan and New Zealand.
~2 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
{{Drugbox | drug_name = | IUPAC_name = 4-{(1R)-2-[(6-{2-[(2,6-Dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol | image = Vilanterol.svg | image_class = skin-invert-image | width = 220 | alt = | caption = | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = B3 | pregnancy_US = | pregnancy_category = | licence_EU = yes | legal_AU = S4 | legal_CA = | legal_UK = POM | legal_US = Rx-only | legal_status = Rx-only | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number = 503068-34-6 | ATCvet = | ATC_prefix = R03 | ATC_suffix = AK10 | ATC_supplemental = (+fluticasone) (+umeclidinium) | PubChem = 10184665 | UNII_Ref = | UNII = 028LZY775B | ChemSpiderID = 8360167 | IUPHAR_ligand = 7353 | DrugBank = | ChEBI = 75037 | ChEMBL = 1198857 | KEGG = D09696
| C = 24 | H = 33 | Cl = 2 | N = 1 | O = 5 | smiles = c1cc(c(c(c1)Cl)COCCOCCCCCCNC[C@@H](c2ccc(c(c2)CO)O)O)Cl | StdInChI = 1S/C24H33Cl2NO5/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28/h5-9,14,24,27-30H,1-4,10-13,15-17H2/t24-/m0/s1 | StdInChIKey = DAFYYTQWSAWIGS-DEOSSOPVSA-N }}
Excerpted from Wikipedia’s “vilanterol” article, available under the CC BY-SA 4.0 licence.